30 de setembro de 2020

Medication Development for the Treatment of Cocaine Addiction – Progress at Preclinical and Clinical Levels

25 de outubro de 20122min

Zheng-Xiong Xi
National Institute on Drug Abuse, Intramural Research Program,
National Institutes of Health, Baltimore, MD – USA

Cocaine addiction continues to be an important public health problem in the United States and other countries. Acute cocaine produces potent rewarding and psychostimulant effects primarily by blocking dopamine (DA) transporters (DAT) in the brain’s reward system – the mesocorticolimbic DA system. However, repeated use of cocaine leads to addiction, persistent craving and a high risk of relapse.

To date, there are no proven pharmacotherapies for cocaine addiction. Recent progress in the neurobiology of drug dependence in preclinical animal models has lead to the discovery of various novel compounds that appear to be promising for the treatment of drug addiction.

pdf intech-medication_development_for_the_treatment_of_cocaine_addiction_progress_at_preclinical_and_clinical_levels.pdf


Sobre a UNIAD

A Unidade de Pesquisa em álcool e Drogas (UNIAD) foi fundada em 1994 pelo Prof. Dr. Ronaldo Laranjeira e John Dunn, recém-chegados da Inglaterra. A criação contou, na época, com o apoio do Departamento de Psiquiatria da UNIFESP. Inicialmente (1994-1996) funcionou dentro do Complexo Hospital São Paulo, com o objetivo de atender funcionários dependentes.



Newsletter